Erik Berntorp
221 – 230 of 334
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2007
-
Mark
Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation
(
- Contribution to journal › Article
-
Mark
Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin (R)): a prospective study of 50 patients
(
- Contribution to journal › Article
-
Mark
VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice.
(
- Contribution to journal › Article
- 2006
-
Mark
Options for treating acute bleeds in addition to bypassing agents: extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics.
(
- Contribution to journal › Article
-
Mark
Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A
(
- Contribution to journal › Article
-
Mark
Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A.
(
- Contribution to journal › Article
-
Mark
Polymorphisms in the IL-10 but not in the IL-1{beta} and IL-4 genes are associated with inhibitor development in patients with hemophilia A.
(
- Contribution to journal › Article
-
Mark
The 80th anniversary of von Willebrand's disease: history, management and research
(
- Contribution to journal › Scientific review
-
Mark
The next generation of hemophilia treatment specialists
(
- Contribution to journal › Article